NOVAST Laboratories, Limited (SHE:301569)

Market Cap	16.24B
Revenue (ttm)	1.01B +16.6%
Net Income	311.22M +19.6%
EPS	0.41 +20.4%
Shares Out	891.60M
PE Ratio	44.52
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,387,140
Open	16.98
Previous Close	17.78
Day's Range	16.98 - 19.45
52-Week Range	16.75 - 42.15
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 17, 2026

About NOVAST Laboratories

NOVAST Laboratories, Limited develops, manufactures, and sells prescription drug formulations. The company produces controlled-release formulations, including extended-release and sustained-release tablets and capsules, as well as low-dose drug formulations. Its products include Metoprolol Succinate Extended-Release Tablets, Nifedipine Extended-Release Tablets, Diltiazem Hydrochloride Extended-Release Capsules, Metformin Hydrochloride Sustained-Release Tablets, Levonorgestrel Tablets, Memantine Hydrochloride Extended-Release Capsules, Quetiapin...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2005
• Employees: 709
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301569

Financial Performance

In 2025, NOVAST Laboratories's revenue was 895.47 million, an increase of 3.38% compared to the previous year's 866.22 million. Earnings were 227.82 million, a decrease of -12.43%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 30, 2026

Data Sources Report a data error